Honduras vs Sao Tome and Principe: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Honduras
86.0%
in 2025
Sao Tome and Principe
86.0%
in 2025
Honduras rank
92nd
Sao Tome and Principe rank
92nd
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Honduras
- Sao Tome and Principe
How they compare
Honduras currently reports 86.0% against 86.0% in Sao Tome and Principe, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Sao Tome and Principe ahead.
Honduras ranks 92nd and Sao Tome and Principe ranks 92nd of 194 countries.
Across the 3 decades both report, Honduras averaged higher in 1 and Sao Tome and Principe in 1.
Head to head by decade
| Decade | Honduras | Sao Tome and Principe | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 83.7% | 66.9% | 16.8% | Honduras |
| 2020s | 87.8% | 90.5% | 2.7% | Sao Tome and Principe |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Honduras or Sao Tome and Principe?
- Honduras, at 86.0% against 86.0% in Sao Tome and Principe as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Honduras and Sao Tome and Principe?
- 0.0%, with Honduras ahead.
- How many years of comparable data are there for Honduras and Sao Tome and Principe?
- 18 years are reported by both, from 2008 to 2025.
- How do Honduras and Sao Tome and Principe rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Honduras ranks 92nd and Sao Tome and Principe ranks 92nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.